Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

被引：0
|
作者：
Marc De Hert
Johan Detraux
Ruud van Winkel
Weiping Yu
Christoph U. Correll
机构：
[1] University Psychiatric Center,Department of Psychiatry and Psychology
[2] Catholic University Leuven,undefined
[3] South Limburg Mental Health Research and Teaching Network,undefined
[4] Maastricht University Medical Center,undefined
[5]  The Zucker Hillside Hospital,undefined
[6] Psychiatry Research,undefined
来源：
Nature Reviews Endocrinology | 2012年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The contribution of antipsychotic medications to an increased risk of type 2 diabetes mellitus and cardiovascular disease is controversial. Despite existing guidelines and recommendations, many antipsychotic-drug-treated patients are not routinely assessed for metabolic and cardiac risk factors. This Review outlines the metabolic and cardiovascular risks of various antipsychotic medications in adults and children, defines the disparities in health care and makes recommendations for screening and monitoring of patients taking these agents.
引用
收藏
页码：114 / 126
页数：12
相关论文
共 50 条
  • [21] ADVERSE METABOLIC EFFECTS OF ANTIPARASITIC DRUGS
    KATZ, M
    REVIEWS OF INFECTIOUS DISEASES, 1982, 4 (04): : 768 - 770
  • [22] Acute effects of antipsychotic drugs on cardiovascular responses to stress
    van den Buuse, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 464 (01) : 55 - 62
  • [23] Metabolic side-effects of novel antipsychotic drugs
    Kovak-Mufic, Ana
    Karlovic, Dalibor
    Martinac, Marko
    Marcinko, Darko
    Letinic, Katica
    Vidrih, Branka
    BIOCHEMIA MEDICA, 2007, 17 (02) : 178 - 187
  • [24] Clinical improvement and metabolic effects of antipsychotic drugs in schizophrenia
    Olszewska, K.
    Rybakowski, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S414 - S415
  • [25] Cardiovascular and metabolic risks associated with schizophrenia and antipsychotic drug treatment
    Meltzer, HY
    JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 : 3 - 4
  • [26] Pharmacogenomics of Cardiovascular Drugs and Adverse Effects in Pediatrics
    Visscher, Henk
    Amstutz, Ursula
    Sistonen, Johanna
    Ross, Colin J.
    Hayden, Michael R.
    Carleton, Bruce C.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2011, 58 (03) : 228 - 239
  • [27] High prevalence of metabolic risk factors associated with cardiovascular disease in schizophrenic patients treated with atypical antipsychotic drugs
    Larsen, JT
    Fagerquist, M
    Holdrup, M
    Christensen, B
    Sigalin, C
    Nilsson, P
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S512 - S513
  • [28] Risks of adverse cardiovascular outcomes associated with antipsychotic use in people with dementia
    Mok, Pearl L. H.
    Carr, Matthew J.
    Guthrie, Bruce
    Morales, Daniel
    van Staa, Tjeerd
    Avery, Antony J.
    Ashcroft, Darren M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 481 - 481
  • [29] Adverse effects associated with antipsychotic use in older adults
    Khalid, Javeria
    Aparasu, Rajender R.
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (09) : 1157 - 1171
  • [30] Antipsychotic drugs and metabolic disorders
    Vasileios Athyros
    Annals of General Psychiatry, 5 (Suppl 1)
12345